Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Lubaid Saleh, Caroline Wilson & Ingunn Holen. (2020) CDK4/6 inhibitors in breast cancer – from in vitro models to clinical trials. Acta Oncologica 59:2, pages 219-232.
Read now
Read now
Burak Bilgin, Mehmet A.N. Sendur, Didem Şener Dede, Muhammed Bülent Akıncı & Bülent Yalçın. (2017) A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer. Current Medical Research and Opinion 33:9, pages 1559-1569.
Read now
Read now
Articles from other publishers (36)
Jing Wang, Jiaxin Zhang, Qinglong Ma, Shasha Zhang, Fengdie Ma, Wei Su, Taotao Zhang, Xiaodong Xie & Cuixia Di. (2023)
Influence of cyclin
D1
splicing variants expression on breast cancer chemoresistance via
CDK4
/
CyclinD1‐pRB‐E2F1
pathway
. Journal of Cellular and Molecular Medicine 27:7, pages 991-1005.
Crossref
Crossref
Qingdan Gu, Jiazhen Zou, Ying Zhou & Qiuchan Deng. (2023) Mechanism of inflammasomes in cancer and targeted therapies. Frontiers in Oncology 13.
Crossref
Crossref
Manzoor Ahmad Mir, Aabida Gul, Shazia Sofi & M. Sultan Khan. 2023. Therapeutic potential of Cell Cycle Kinases in Breast Cancer. Therapeutic potential of Cell Cycle Kinases in Breast Cancer
313
333
.
Jason N. Abrams. (2022) Design, Synthesis, and In Vitro Mitotic Evaluation of 3‐Amino‐Isoquinolinones as Anticancer Agents. ChemistrySelect 7:42.
Crossref
Crossref
Mona Sadeghalvad, Kamran Mansouri, Hamid-Reza Mohammadi-Motlagh, Farshid Noorbakhsh, Ali Mostafaie, Sadaf Alipour & Nima Rezaei. (2022) Long non-coding RNA HOTAIR induces the PI3K/AKT/mTOR signaling pathway in breast cancer cells. Revista da Associação Médica Brasileira 68:4, pages 456-462.
Crossref
Crossref
Shuanghu Wang, Xueying Tan, Quan Zhou, Peiwu Geng, Jinhui Wang, Ping Zou, Aiping Deng & Jingbo Hu. (2021) RETRACTED ARTICLE: Co-delivery of doxorubicin and SIS3 by folate-targeted polymeric micelles for overcoming tumor multidrug resistance. Drug Delivery and Translational Research 12:1, pages 167-179.
Crossref
Crossref
Amir Sadra Zangouei, Maliheh Alimardani & Meysam Moghbeli. (2021) MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells. Cancer Cell International 21:1.
Crossref
Crossref
Ghazaleh Khalili-Tanha & Meysam Moghbeli. (2021) Long non-coding RNAs as the critical regulators of doxorubicin resistance in tumor cells. Cellular & Molecular Biology Letters 26:1.
Crossref
Crossref
Jiaying He, Shaomi Zhu, Xin Liang, Qinxiu Zhang, Xiaohong Luo, Chi Liu & Linjiang Song. (2021) LncRNA as a multifunctional regulator in cancer multi-drug resistance. Molecular Biology Reports 48:8, pages 1-15.
Crossref
Crossref
Ahmed Mohamed Etman, Sherif Sabry Abdel Mageed, Mohamed Ahmed Ali & Mahmoud Abd El Monem El Hassab. (2021) Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story. Current Chemical Biology 15:2, pages 139-162.
Crossref
Crossref
Oumaima Zidi, Nessrine Souai, Henda Raies, Farhat Ben Ayed, Amel Mezlini, Sonia Mezrioui, Fabrice Tranchida, Jean-Marc Sabatier, Amor Mosbah, Ameur Cherif, Laetitia Shintu & Soumaya Kouidhi. (2021) Fecal Metabolic Profiling of Breast Cancer Patients during Neoadjuvant Chemotherapy Reveals Potential Biomarkers. Molecules 26:8, pages 2266.
Crossref
Crossref
John F.R. Robertson, Abigail Evans, Stephan Henschen, Cliona C. Kirwan, Ali Jahan, Laura M. Kenny, J. Michael Dixon, Peter Schmid, Ashutosh Kothari, Omar Mohamed, Peter A. Fasching, Kwok-Leung Cheung, Rachel Wuerstlein, Danielle Carroll, Teresa Klinowska, Justin P.O. Lindemann, Alexander MacDonald, Richard Mather, Rhiannon Maudsley, Michele Moschetta, Myria Nikolaou, Martine P. Roudier, Tinnu Sarvotham, Gaia Schiavon, Diansong Zhou, Li Zhou & Nadia Harbeck. (2020) A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer. Clinical Cancer Research 26:16, pages 4242-4249.
Crossref
Crossref
Cheng Tao, Jian Chen, Xiaofei Huang, Zide Chen, Xinping Li, Yinghong Li, Youqin Xu, Min Ma & Zhengzhi Wu. (2020) CT1-3, a novel magnolol-sulforaphane hybrid suppresses tumorigenesis through inducing mitochondria-mediated apoptosis and inhibiting epithelial mesenchymal transition. European Journal of Medicinal Chemistry 199, pages 112441.
Crossref
Crossref
Xiping Zhang & Hongjian Yang. (2020) Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer. Clinical Breast Cancer 20:4, pages 275-282.
Crossref
Crossref
Maria A. Papadaki, Anastasios V. Koutsopoulos, Panormitis G. Tsoulfas, Eleni Lagoudaki, Despoina Aggouraki, Alexia Monastirioti, Chara Koutoulaki, Christina A. Apostolopoulou, Aikaterini C. Merodoulaki, Chara Papadaki, Dimitrios Mavroudis & Sofia Agelaki. (2020) Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer. Cancers 12:2, pages 376.
Crossref
Crossref
Shu Lin, Lifeng Yu, Xinyue Song, Jia Bi, Longyang Jiang, Yan Wang, Miao He, Qinghuan Xiao, Mingli Sun, Olufunmilayo I. Olopade, Lin Zhao & Minjie Wei. (2019) Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. Cell Death & Disease 10:9.
Crossref
Crossref
Zhixiang Li, Jun Qian, Jing Li & Chao Zhu. (2019) Knockdown of lncRNA‑HOTAIR downregulates the drug‑resistance of breast cancer cells to doxorubicin via the PI3K/AKT/mTOR signaling pathway. Experimental and Therapeutic Medicine.
Crossref
Crossref
Qing Ma, Yang Gao, Pei Xu, Kai Li, Xiaolong Xu, Jingbo Gao, Yuwen Qi, Jingjing Xu, Yan Yang, Wenjing Song, Xin He, Shuting Liu, Xiaoning Yuan, Weinan Yin, Yanqi He, Wenting Pan, Lei Wei & Jingwei Zhang. (2019) Atorvastatin Inhibits Breast Cancer Cells by Downregulating PTEN/AKT Pathway via Promoting Ras Homolog Family Member B (RhoB). BioMed Research International 2019, pages 1-15.
Crossref
Crossref
Burak Bilgin, Mehmet AN Şendur, Mutlu Hızal, Muhammed Bülent Akıncı, Didem Şener Dede & Bülent Yalçın. (2019) Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer. Future Oncology 15:2, pages 105-107.
Crossref
Crossref
Claudia Busonero, Stefano Leone, Stefania Bartoloni & Filippo Acconcia. (2019) Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer. Molecular and Cellular Endocrinology 480, pages 107-121.
Crossref
Crossref
Zilin Li, Shen Kiat Lim, Xu Liang & Yoon Pin Lim. (2018) The transcriptional coactivator WBP2 primes triple-negative breast cancer cells for responses to Wnt signaling via the JNK/Jun kinase pathway. Journal of Biological Chemistry 293:52, pages 20014-20028.
Crossref
Crossref
M. Orditura, C.M. Della Corte, A. Diana, V. Ciaramella, E. Franzese, V. Famiglietti, I. Panarese, R. Franco, A. Grimaldi, A. Lombardi, M. Caraglia, A. Santoriello, E. Procaccini, E. Lieto, E. Maiello, F. De Vita, F. Ciardiello & F. Morgillo. (2018) Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs. The Breast 41, pages 165-171.
Crossref
Crossref
Ju-Min Chen, Jun-Yun Bai & Kun-Xian Yang. (2018) Effect of resveratrol on doxorubicin resistance in breast neoplasm cells by modulating PI3K/Akt signaling pathway. IUBMB Life 70:6, pages 491-500.
Crossref
Crossref
Hehui Fang, Doudou Huang, Fang Yang & Xiaoxiang Guan. (2017) Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer. Breast Cancer Research and Treatment 168:2, pages 287-297.
Crossref
Crossref
Shuo Wang, Kai Wang, Huaiquan Wang, Jiankui Han & Hukui Sun. (2017) Autophagy is essential for flavopiridol-induced cytotoxicity against MCF-7 breast cancer cells. Molecular Medicine Reports 16:6, pages 9715-9720.
Crossref
Crossref
Floriana Morgillo, Carminia Maria Della Corte, Anna Diana, Concetta di Mauro, Vincenza Ciaramella, Giusi Barra, Valentina Belli, Elisena Franzese, Roberto Bianco, Evaristo Maiello, Ferdinando De Vita, Fortunato Ciardiello & Michele Orditura. (2017) Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells. Oncotarget 8:44, pages 76479-76491.
Crossref
Crossref
Srinuvasarao Rayavarapu, Nagendra Sastry Yarla, Sunanda Kumari Kadiri, Anupam Bishayee, Siddaiah Vidavalur, Ramu Tadikonda, Mahaboob Basha, Vijaya Rao Pidugu, Kaladhar S. V. G. K. Dowluru, Dhananjaya Bhadrapura Lakappa, Mohammad A. Kamal, Ghulam Md Ashraf, Vadim V. Tarasov, Vladimir N. Chubarev, Sergey G. Klochkov, George E. Barreto, Sergey O. Bachurin & Gjumrakch Aliev. (2017) Synthesis of Saccharumoside-B analogue with potential of antiproliferative and pro-apoptotic activities. Scientific Reports 7:1.
Crossref
Crossref
Hazel M. Weir, Robert H. Bradbury, Mandy Lawson, Alfred A. Rabow, David Buttar, Rowena J. Callis, Jon O. Curwen, Camila de Almeida, Peter Ballard, Michael Hulse, Craig S. Donald, Lyman J.L. Feron, Galith Karoutchi, Philip MacFaul, Thomas Moss, Richard A. Norman, Stuart E. Pearson, Michael Tonge, Gareth Davies, Graeme E. Walker, Zena Wilson, Rachel Rowlinson, Steve Powell, Claire Sadler, Graham Richmond, Brendon Ladd, Ermira Pazolli, Anne Marie Mazzola, Celina D'Cruz & Chris De Savi. (2016)
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and
ESR1
-Mutant Breast Tumors in Preclinical Models
. Cancer Research 76:11, pages 3307-3318.
Crossref
Crossref
Adam J. DiPippo, Neelam K. Patel & Chad M. Barnett. (2016) Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:6, pages 652-667.
Crossref
Crossref
Katarzyna Chojnacka & Dolores D. Mruk. (2015) The Src non-receptor tyrosine kinase paradigm: New insights into mammalian Sertoli cell biology. Molecular and Cellular Endocrinology 415, pages 133-142.
Crossref
Crossref
Yanwei Luo, Xinye Wang, Heran Wang, Yang Xu, Qiuyuan Wen, Songqing Fan, Ran Zhao, Shihe Jiang, Jing Yang, Yukun Liu, Xiayu Li, Wei Xiong, Jian Ma, Shuping Peng, Zhaoyang Zeng, Xiaoling Li, Joshua B. Phillips, Guiyuan Li, Ming Tan & Ming Zhou. (2015) High Bak Expression Is Associated with a Favorable Prognosis in Breast Cancer and Sensitizes Breast Cancer Cells to Paclitaxel. PLOS ONE 10:9, pages e0138955.
Crossref
Crossref
Monica Faronato, Van T.M. Nguyen, Darren K. Patten, Ylenia Lombardo, Jennifer H. Steel, Naina Patel, Laura Woodley, Sami Shousha, Giancarlo Pruneri, R. Charles Coombes & Luca Magnani. (2015) DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through notch hyper-activation. Oncotarget 6:26, pages 22467-22479.
Crossref
Crossref
Shulin Xiang, Robert T. Dauchy, Adam Hauch, Lulu Mao, Lin Yuan, Melissa A. Wren, Victoria P. Belancio, Debasis Mondal, Tripp Frasch, David E. Blask & Steven M. Hill. (2015) Doxorubicin resistance in breast cancer is driven by light at night-induced disruption of the circadian melatonin signal. Journal of Pineal Research 59:1, pages 60-69.
Crossref
Crossref
Marta Kovatcheva, David D. Liu, Mark A. Dickson, Mary E. Klein, Rachael O’Connor, Fatima O. Wilder, Nicholas D. Socci, William D. Tap, Gary K. Schwartz, Samuel Singer, Aimee M. Crago & Andrew Koff. (2015) MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition. Oncotarget 6:10, pages 8226-8243.
Crossref
Crossref
Yan Zhou, Hai-yan Hu, Wei Meng, Ling Jiang, Xing Zhang, Jing-jing Sha, Zhigang Lu & Yang Yao. (2014) MEK inhibitor effective against proliferation in breast cancer cell. Tumor Biology 35:9, pages 9269-9279.
Crossref
Crossref
Paola Maycotte. (2014) Targeting autophagy in breast cancer. World Journal of Clinical Oncology 5:3, pages 224.
Crossref
Crossref